文献速递泌尿男性生殖肿瘤

奥拉帕利联合或不联合西地尼布治疗转移性去势抵抗性前列腺癌的随机试验:美国国家癌症研究所9984研究结果

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
PubMed 文献 · J Clin Oncol · 2022-10-18

这项随机试验将90例进展性转移性去势抵抗性前列腺癌患者按1:1分配至西地尼布30mg每日一次联合奥拉帕利200mg每日两次组(A组)或奥拉帕利300mg每日两次单药组(B组)。意向治疗人群中,A组中位影像学无进展生存期(rPFS)为8.5个月,B组为4.0个月,联合组显著改善rPFS(HR 0.617,95%CI 0.392-0.969,P=0.0359),但3-4级不良事件发生率A组为61%,B组为18%。

要点

  • 西地尼布联合奥拉帕利较奥拉帕利单药显著改善mCRPC患者rPFS(HR 0.617,P=0.0359)。
  • 联合组3-4级不良事件发生率为61%,单药组为18%。
  • BRCA2突变亚组中联合组与单药组的中位rPFS数值上更长。

核心结论

  • 在转移性去势抵抗性前列腺癌男性患者中,西地尼布联合奥拉帕利较奥拉帕利单药改善rPFS。
  • 该联合方案与3-4级不良事件发生率增加相关。
  • 接受奥拉帕利联合或不联合西地尼布治疗的BRCA2突变亚组中位rPFS在数值上更长。

研究设计与样本

  • 随机试验将进展性转移性去势抵抗性前列腺癌患者按1:1随机分配至A组(西地尼布30mg每日一次联合奥拉帕利200mg每日两次)或B组(奥拉帕利300mg每日两次单药)。
  • 主要终点为意向治疗人群的影像学无进展生存期(rPFS)。
  • 次要终点为HRR缺陷型和HRR功能正常型mCRPC患者的rPFS。
  • 意向治疗集共90例患者。

主要发现

  • 意向治疗集90例患者中,A组中位rPFS为8.5个月(95%CI 5.4-12.0),B组为4.0个月(95%CI 3.2-8.5)。
  • 西地尼布联合奥拉帕利较奥拉帕利单药显著改善rPFS(HR 0.617,95%CI 0.392-0.969,P=0.0359)。
  • HRR缺陷型mCRPC患者中,A组中位rPFS为10.6个月(95%CI 5.9-未评估[NA]),B组为3.8个月(95%CI 2.33-NA),HR 0.64(95%CI 0.272-1.504)。
  • BRCA2突变mCRPC患者中,A组中位rPFS为13.8个月(95%CI 3.3-NA),B组为11.3个月(95%CI 3.8-NA),HR 0.98(95%CI 0.321-2.988)。
  • 3-4级不良事件发生率A组为61%,B组为18%。

局限性

  • HRR缺陷型和BRCA2突变亚组分析为描述性分析,其HR的95%CI跨1,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cediranib, a pan-vascular endothelial growth factor receptor inhibitor, suppresses expression of homologous recombination repair (HRR) genes and increases sensitivity to poly-(ADP-ribose) polymerase inhibition in preclinical models. We investigated whether cediranib combined with olaparib improves the clinical outcomes of patients with prostate cancer. METHODS: Patients with progressive metastatic castration-resistant prostate cancer (mCRPC) were randomly assigned 1:1 to arm A: cediranib 30 mg once daily plus olaparib 200 mg twice daily or arm B: olaparib 300 mg twice daily alone. The primary end point was radiographic progression-free survival (rPFS) in the intention-to-treat patients. The secondary end points were rPFS in patients with HRR-deficient and HRR-proficient mCRPC. RESULTS: In the intention-to-treat set of 90 patients, median rPFS was 8.5 (95% CI, 5.4 to 12.0) and 4.0 (95% CI, 3.2 to 8.5) months in arms A and B, respectively. Cediranib/olaparib significantly improved rPFS versus olaparib alone (hazard ratio [HR], 0.617; 95% CI, 0.392 to 0.969; P = .0359). Descriptive analyses showed a median rPFS of 10.6 (95% CI, 5.9 to not assessed [NA]) and 3.8 (95% CI, 2.33 to NA) months (HR, 0.64; 95% CI, 0.272 to 1.504) among patients with HRR-deficient mCRPC, and 13.8 (95% CI, 3.3 to NA) and 11.3 (95% CI, 3.8 to NA) months (HR, 0.98; 95% CI, 0.321 to 2.988) among patients with BRCA2-mutated mCRPC in arms A and B, respectively. The incidence of grades 3-4 adverse events was 61% and 18% in arms A and B, respectively. CONCLUSION: Cediranib combined with olaparib improved rPFS compared with olaparib alone in men with mCRPC. This combination was associated with an increased incidence of grades 3-4 adverse events. BRCA2-mutated subgroups treated with olaparib with or without cediranib were associated with a numerically longer median rPFS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kim JW, McKay RR, Radke MR, et al. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2022. PMID: 36256912. doi:10.1200/JCO.21.02947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。